View ValuationSudeep Pharma 将来の成長Future 基準チェック /26Sudeep Pharmaは、10.4%と19.4%でそれぞれ年率10.4%で利益と収益が成長すると予測される一方、EPSはgrowで10.2%年率。主要情報10.4%収益成長率10.21%EPS成長率Chemicals 収益成長16.2%収益成長率19.4%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日17 Aug 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹1,108, the stock trades at a forward P/E ratio of 62x. Average forward P/E is 26x in the Chemicals industry in India.New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Aug 05Sudeep Pharma Limited Announces Board ChangesSudeep Pharma Limited at its 37th AGM held on 4 August 2026 approved appointment of Mr. Milin Mehta as a Director (Non-Executive and Non- Independent) and to Change the Remuneration of Mr. Ajay Shrirang Kandelkar (DIN: 10773491) as Whole Time Director with effect from 1st April 2026.お知らせ • Jul 25Sudeep Pharma Limited to Report Q1, 2027 Results on Aug 04, 2026Sudeep Pharma Limited announced that they will report Q1, 2027 results on Aug 04, 2026Reported Earnings • Jul 14Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.42b (up 28% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 27% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.お知らせ • Jul 11Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026, at 11:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹870, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 29x in the Chemicals industry in India.分析記事 • May 29Sudeep Pharma's (NSE:SUDEEPPHRM) Solid Earnings May Rest On Weak FoundationsFollowing the solid earnings report from Sudeep Pharma Limited ( NSE:SUDEEPPHRM ), the market responded by bidding up...Reported Earnings • May 23Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.71b (up 34% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 26% (down from 28% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India.お知らせ • May 14Sudeep Pharma Limited to Report Q4, 2026 Results on May 21, 2026Sudeep Pharma Limited announced that they will report Q4, 2026 results on May 21, 2026Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹4.29 (vs ₹4.07 in 3Q 2025)Third quarter 2026 results: EPS: ₹4.29 (up from ₹4.07 in 3Q 2025). Revenue: ₹1.79b (up 14% from 3Q 2025). Net income: ₹474.6m (up 7.4% from 3Q 2025). Profit margin: 27% (down from 28% in 3Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Feb 02Sudeep Pharma Limited to Report Q3, 2026 Results on Feb 06, 2026Sudeep Pharma Limited announced that they will report Q3, 2026 results on Feb 06, 2026Reported Earnings • Dec 20Second quarter 2026 earnings released: EPS: ₹4.20 (vs ₹4.07 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.20 (up from ₹4.07 in 2Q 2025). Revenue: ₹1.73b (up 9.7% from 2Q 2025). Net income: ₹457.5m (up 3.5% from 2Q 2025). Profit margin: 27% (down from 28% in 2Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Dec 15Sudeep Pharma Limited to Report Q2, 2026 Results on Dec 19, 2025Sudeep Pharma Limited announced that they will report Q2, 2026 results on Dec 19, 2025Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Raghunandan Rao was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.業績と収益の成長予測NSEI:SUDEEPPHRM - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20289,3812,187-344N/A23/31/20277,2761,954435N/A16/30/20266,7561,826N/AN/AN/A3/31/20266,4231,729-158696N/A12/31/20256,1751,682N/AN/AN/A9/30/20255,6071,495-233412N/A6/30/20255,1251,366-339306N/A3/31/20255,0201,387-155487N/A3/31/20244,5931,332157657N/A3/31/20234,28762312484N/A3/31/20223,446498-604-26N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SUDEEPPHRMの予測収益成長率 (年間10.4% ) は 貯蓄率 ( 6.9% ) を上回っています。収益対市場: SUDEEPPHRMの収益 ( 10.4% ) Indian市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: SUDEEPPHRMの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SUDEEPPHRMの収益 ( 19.4% ) Indian市場 ( 11.2% ) よりも速いペースで成長すると予測されています。高い収益成長: SUDEEPPHRMの収益 ( 19.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SUDEEPPHRMの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/21 15:35終値2026/08/21 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sudeep Pharma Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Sanjesh JainICICI Securities Ltd.Swarnendu BhushanPrabhudas Lilladher Pvt Ltd.
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹1,108, the stock trades at a forward P/E ratio of 62x. Average forward P/E is 26x in the Chemicals industry in India.
New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Aug 05Sudeep Pharma Limited Announces Board ChangesSudeep Pharma Limited at its 37th AGM held on 4 August 2026 approved appointment of Mr. Milin Mehta as a Director (Non-Executive and Non- Independent) and to Change the Remuneration of Mr. Ajay Shrirang Kandelkar (DIN: 10773491) as Whole Time Director with effect from 1st April 2026.
お知らせ • Jul 25Sudeep Pharma Limited to Report Q1, 2027 Results on Aug 04, 2026Sudeep Pharma Limited announced that they will report Q1, 2027 results on Aug 04, 2026
Reported Earnings • Jul 14Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.42b (up 28% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 27% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
お知らせ • Jul 11Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026, at 11:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹870, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 29x in the Chemicals industry in India.
分析記事 • May 29Sudeep Pharma's (NSE:SUDEEPPHRM) Solid Earnings May Rest On Weak FoundationsFollowing the solid earnings report from Sudeep Pharma Limited ( NSE:SUDEEPPHRM ), the market responded by bidding up...
Reported Earnings • May 23Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.71b (up 34% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 26% (down from 28% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India.
お知らせ • May 14Sudeep Pharma Limited to Report Q4, 2026 Results on May 21, 2026Sudeep Pharma Limited announced that they will report Q4, 2026 results on May 21, 2026
Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹4.29 (vs ₹4.07 in 3Q 2025)Third quarter 2026 results: EPS: ₹4.29 (up from ₹4.07 in 3Q 2025). Revenue: ₹1.79b (up 14% from 3Q 2025). Net income: ₹474.6m (up 7.4% from 3Q 2025). Profit margin: 27% (down from 28% in 3Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Feb 02Sudeep Pharma Limited to Report Q3, 2026 Results on Feb 06, 2026Sudeep Pharma Limited announced that they will report Q3, 2026 results on Feb 06, 2026
Reported Earnings • Dec 20Second quarter 2026 earnings released: EPS: ₹4.20 (vs ₹4.07 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.20 (up from ₹4.07 in 2Q 2025). Revenue: ₹1.73b (up 9.7% from 2Q 2025). Net income: ₹457.5m (up 3.5% from 2Q 2025). Profit margin: 27% (down from 28% in 2Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Dec 15Sudeep Pharma Limited to Report Q2, 2026 Results on Dec 19, 2025Sudeep Pharma Limited announced that they will report Q2, 2026 results on Dec 19, 2025
Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Raghunandan Rao was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.